BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 59 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9 | -93.5% | 41,700 | -37.9% | 0.00% | – |
| Q2 2023 | $139 | -61.1% | 67,200 | -37.8% | 0.00% | – |
| Q1 2023 | $357 | +101.7% | 108,000 | 0.0% | 0.00% | – |
| Q4 2022 | $177 | -100.0% | 108,000 | 0.0% | 0.00% | – |
| Q3 2022 | $478,000 | +86.0% | 108,000 | +16.1% | 0.00% | – |
| Q2 2022 | $257,000 | -17.6% | 93,000 | 0.0% | 0.00% | – |
| Q1 2022 | $312,000 | -16.1% | 93,000 | 0.0% | 0.00% | – |
| Q4 2021 | $372,000 | +21.2% | 93,000 | 0.0% | 0.00% | – |
| Q3 2021 | $307,000 | -13.0% | 93,000 | 0.0% | 0.00% | – |
| Q2 2021 | $353,000 | -24.6% | 93,000 | -23.9% | 0.00% | – |
| Q1 2021 | $468,000 | +372.7% | 122,161 | +460.2% | 0.00% | – |
| Q4 2020 | $99,000 | -44.4% | 21,806 | +107.3% | 0.00% | – |
| Q3 2020 | $178,000 | – | 10,520 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |